Phase III data offer hope to patients with opioid-induced constipation

摘要

Phase III study data have shown that the selective peripheral opioid-receptor antagonist alvimopan can relieve the symptoms of opioid-induced constipation(OIC).The 12-week study enrolled 518 patients suffering from non-cancer pain and with OIC symptoms,defined as having fewer than three weekly spontaneous bowel movements(SBMs)plus one or more bowel movement symptoms(incomplete evacuation,straining,hard/small pellets)for at least 25 per cent of bowel movements.Patients were then randomised to receive either alvimopan or placebo.